February 7, 2024Open Access

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Key Points

Key points are not available for this paper at this time.

Abstract

Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Stephen A. Harrison

Pierre Bédossa

Cynthia D. Guy

Journals

New England Journal of Medicine

Actions

Institutions

University of Oxford

University of California, San Diego

University of Chicago

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study